Venus Remedies Ltd, one of India’s leading manufacturers of generic drugs, has been awarded its first disbursement of Rs 7.5 crore under the Central government’s Production Linked Incentive (PLI) scheme for the financial year 2022-23, which covers 75% of the total incentive due to the company for the year.Having been selected as one of the […]
Tag: Saransh Chaudhary
Venus Remedies gets coveted GMP certification from Libya
Venus Remedies, a globally recognised pharmaceutical company, has been awarded the Good Manufacturing Practices (GMP) certification for its facilities from the Ministry of Health, Libya. This accomplishment is a testament to the company’s commitment to quality, safety and efficiency in the production of injectable pharmaceuticals, including oncology, antibiotic and anticoagulant medications. Mr. Saransh Chaudhary, CEO […]
Venus Remedies gets coveted GMP certification from Libya
Venus Remedies, a globally recognised pharmaceutical company, has been awarded the Good Manufacturing Practices (GMP) certification for its facilities from the Ministry of Health, Libya. This accomplishment is a testament to the company’s commitment to quality, safety and efficiency in the production of injectable pharmaceuticals, including oncology, antibiotic and anticoagulant medications. Mr. Saransh Chaudhary, CEO […]
Venus Remedies on expansion spree in Gulf, gets Saudi marketing approval for Enoxaparin in PFS
Making rapid global strides by expanding its reach in the Gulf, Venus Remedies Ltd, a leading exporter of affordable generic drugs with presence in more than 80 countries, has received marketing approval from Saudi Arabia, the largest pharmaceutical market in the Gulf Cooperation Council (GCC) region, for its product Enoxaparin in pre-filled syringes. Venus Remedies […]
Venus Remedies H1 net profit registers 315% increase
Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953), one of India’s leading research-driven pharmaceutical companies, has posted a 315% increase in net profit in the first half of this financial year as compared to the corresponding period last year. Announcing its unaudited half-yearly financial results for FY 2021-22 for the period April 1 to September 30, […]